NCT00000846View on ClinicalTrials.gov

A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
BIOLOGICAL

HIV-1 Peptide Vaccine, Microparticulate Monovalent

BIOLOGICAL

HIV-1 Peptide Immunogen, Multivalent

Trial Locations (3)

14642

Univ of Rochester Med Ctr, Rochester

35294

Univ of Alabama at Birmingham, Birmingham

98144

Univ of Washington / Pacific Med Ctr, Seattle

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000846 - A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers. | Biotech Hunter | Biotech Hunter